Pioneering a new frontier in the treatment of neurological diseases.

Henrik is a pioneering neuroscientist with a distinguished career in epilepsy research and drug development.  As Vice President for Neuroscience at UCB, he led the team that discovered the novel Synaptic Vesicle 2A (SV2A) mechanism, leading to the development of two groundbreaking antiepileptic drugs: Levetiracetam (Keppra), the first blockbuster epilepsy treatment, and Brivaracetam (Briviact).

In addition to his contributions to drug discovery, Henrik has been engaged in the epilepsy research community. He is a former member of the Scientific Committee at Citizens United for Research in Epilepsy and currently serves on the External Consultant Board of the NIH's Epilepsy Therapy Screening Project.

In recognition of his dedication to advancing epilepsy treatments, Henrik was honored with the Accelerator Award from the US Epilepsy Foundation, celebrating his long-standing commitment to improving the lives of those affected by epilepsy.

Sakari Kauppinen is prior Professor at the Department of Clinical Medicine, Aalborg University and Director of the Center for RNA Medicine. His research focuses on the discovery of RNA-targeted therapeutics for unmet medical needs, and exploring the roles of non-coding RNAs in health and disease.

Before joining Aalborg University, he was Senior Director of miRNA Research & Drug Discovery at Santaris Pharma (acquired by Roche in 2014) where he supervised the discovery of Miravirsen – the world’s first miRNA-targeted drug. As a key member of the clinical development team, he played a pivotal role in advancing Miravirsen to Phase 2 clinical trials, demonstrating on-target efficacy against HCV infection with a strong safety profile.

Sakari is also Co-Founder of Resalis Therapeutics, a clinical-stage company for the treatment of metabolic disorders. In 2019, he received $9.2 M from the Novo Nordisk Foundation to establish a NASH Research Consortium.

Lars Hellerung Christiansen is a Danish biotech entrepreneur and investor with more than 30 years of experience in founding, financing, and developing life‑science companies.

He has co‑founded several successful biotech ventures, including Acadia Pharmaceuticals, Zealand Pharma, Symphogen, Epizyme, Biograil and Prosidion, later acquired by OSI Pharmaceuticals. ‍Throughout his career, Lars Hellerung Christiansen has played a key role in helping early‑stage biotech companies scale by contributing financing, strategic guidance, and company‑building expertise.

His track record includes involvement in three NASDAQ‑listed companies and multiple privately held ventures developing innovative therapeutics and drug‑delivery technologies. As an investor and co‑founder, he contributes decades of experience from biotech entrepreneurship and governance to support the company’s long‑term development and strategic direction.